Work

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Year: 2012

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.190.190

Authors: Herbert Eradat, Sebastian Grosicki, John Catalono, Walter Cosolo, Irina Dyagil, Thomas J Kipps, Beiyao Zheng, Sreeni Yalamanchili, Srikumar Sahasranaman, Deborah Hurst, William Ho, Halyna Pylypenko

Institutions: University of California, Los Angeles, Frankston Hospital, National Academy of Medical Sciences of Ukraine, University of California San Diego, Moores Cancer Center, Genentech

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2980242895

FWCI: 1.155

Cites:

Cited by: 10

Related to: 10